Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 6/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66408 | 0.87 | PIK3CD (0.37) | ACVRL1PIK3CDCSNK2A2CSNK2A1RIPK1 | |
| SCHEMBL28781326 | 0.86 | ACVRL1 (0.38) | ACVRL1PIK3CDCSNK2A2CSNK2A1 | |
| SCHEMBL66411 | 0.84 | PIK3CD (0.42) | ACVRL1PIK3CDCSNK2A2CSNK2A1RIPK1 | |
| SCHEMBL64693 | 0.75 | PIK3CD (0.41) | PIK3CDCSNK2A2CSNK2A1RIPK1 | |
| SCHEMBL65572 | 0.74 | ACVRL1 (0.45) | ACVRL1PIK3CD | |
| SCHEMBL66503 | 0.73 | ALDH1A1 (0.43) | ACVRL1PIK3CD | |
| SCHEMBL65394 | 0.73 | ACVRL1 (0.50) | ACVRL1FGFR1 | |
| SCHEMBL64689 | 0.72 | ACVRL1 (0.55) | ACVRL1PIK3CDRIPK1FGFR1 | |
| SCHEMBL64691 | 0.72 | ACVRL1 (0.59) | ACVRL1PIK3CD | |
| SCHEMBL5074930 | 0.71 | PIK3CD (0.37) | ACVRL1PIK3CDCSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | ACVRL1 941/4885PIK3CD 529/4885CSNK2A2 1432/4885 |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | ACVRL1 963/4885PIK3CD 608/4885CSNK2A2 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.